Multicenter review of a tadalafil suspension formulation for infants and children with pulmonary hypertension: A North American experience

IntroductionPhosphodiesterase type 5 (PDE5) inhibitors, with sildenafil the earliest among them, are widely used in the management of pediatric pulmonary arterial hypertension (PAH). Tadalafil is a PDE5 inhibitor with a long half life (16 h), stable pharmacokinetics and pharmacodynamics, and minimal...

全面介紹

書目詳細資料

發表在:	Frontiers in Pediatrics
Main Authors:	David Edward Youssef, Stephanie S. Handler, Susan Marjorie Richards, Catherine Anne Sheppard, Jenna Smith, Kathryn Tillman, Matthew Pietrosanu, Edward Kirkpatrick, Angela Bates
格式:	Article
語言:	英语
出版:	Frontiers Media S.A. 2023-01-01
主題:	adverse effect echocardiography hemodynamic pulmonary vasodilator safety tolerability
在線閱讀:	https://www.frontiersin.org/articles/10.3389/fped.2023.1055131/full